
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. is positioned as a compelling growth story in the neurology sector, supported by ongoing registrational trials and the sustained commercial success of its flagship product, WAKIX. The company benefits from a strong financial foundation, providing the necessary resources for both internal research and development as well as potential business development opportunities. Despite the setback with ZYN002, the company maintains a positive outlook due to its consistent commercial execution and a robust pipeline of drug candidates that continue to advance.
Bears say
Harmony Biosciences Holdings Inc.'s outlook appears negative primarily due to the failure of its pivotal Phase 3 RECONNECT trial for ZYN002, which did not meet its primary endpoint, reflecting a higher-than-expected placebo response that diluted the drug's treatment efficacy. This setback is significant, as the trial's outcome raises concerns about the product's potential in a critical market segment, specifically for patients with Fragile X syndrome who exhibit substantial unmet medical needs. The reliance on a single product for revenue generation also accentuates the risks associated with further pipeline developments, given the challenges faced in clinical evaluations.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares